newsfilter
← Latest News
Business Wire·

Dicerna Announces First Quarter 2021 Financial Results and Provides a Business Update

– Announced Sale of OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million; Extends Cash Runway Into 2024 – – Earned $25 Million Milestone Payment in Connection With Roche's Initiation of GalXC™ RNAi Candidate RG6346